×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Brielle Benyon
Certain groups of pediatric and adolescent patients are less likely to receive fertility preservation consultation, recent research says.
Michelle Burleigh
An acute promyelocytic leukemia survivor reflects on fear, courage and the future.
LISA MACHADO
Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.
Kristie L. Kahl
In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.
Brian Koffman, M.D.C.M
Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones.
Brielle Benyon
The Food and Drug Administration (FDA) approved Sprycel (dasatinib) plus chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicole Lamanna, M.D., provides insight on how the management of chronic lymphocytic leukemia (CLL) might progress as new therapeutic agents are introduced or matched together.
In the setting of relapsed chronic lymphocytic leukemia, Nicole Lamanna, M.D., considers the patient and disease factors that affect her selection of therapy.
In the context of therapeutic management of chronic lymphocytic leukemia (CLL), Nicole Lamanna, M.D., offers advice regarding lifestyle modifications that may improve outcomes for patients.
Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).